S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:EDIT

Editas Medicine News Headlines

$32.37
-0.93 (-2.79%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$31.92
$33.59
50-Day Range
$32.37
$62.07
52-Week Range
$29.35
$99.95
Volume
830,601 shs
Average Volume
1.89 million shs
Market Capitalization
$2.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.97

Media Mentions By Week



Editas Medicine Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EDIT
News Sentiment

0.83

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EDIT Articles
This Week

3

3

EDIT Articles
Average Week

Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

Editas Medicine (NASDAQ:EDIT) News Headlines Today

SourceHeadline
finance.yahoo.com logoSelecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study
finance.yahoo.com - November 25 at 1:20 PM
finance.yahoo.com logoCRISPR's (CRSP) CAR-T Cell Therapy Gets FDA's RMAT Designation
finance.yahoo.com - November 23 at 1:50 PM
finance.yahoo.com logoThese 40 Mass. companies made the new Deloitte Fast 500 list
finance.yahoo.com - November 17 at 7:29 AM
finance.yahoo.com logoCoherus' (CHRS) Toripalimab Gets Orphan Drug Tag for Rare Cancer
finance.yahoo.com - November 16 at 10:20 AM
MarketBeat logoEditas Medicine, Inc. Forecasted to Post FY2021 Earnings of ($3.01) Per Share (NASDAQ:EDIT)
americanbankingnews.com - November 11 at 6:50 AM
MarketBeat logoEditas Medicine, Inc. (NASDAQ:EDIT) EVP Bruce Eaton Sells 287 Shares
americanbankingnews.com - November 10 at 8:56 PM
finance.yahoo.com logoEditas (EDIT) Q3 Earnings Beat Estimates, Revenues Fall Y/Y
finance.yahoo.com - November 9 at 1:44 PM
MarketBeat logoEditas Medicine (NASDAQ:EDIT) Trading Up 11.5% Following Strong Earnings
americanbankingnews.com - November 8 at 2:48 PM
MarketBeat logoEditas Medicine (NASDAQ:EDIT) Announces Earnings Results
americanbankingnews.com - November 8 at 2:04 PM
finance.yahoo.com logoEditas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 8 at 10:17 AM
MarketBeat logoHead-To-Head Review: Editas Medicine (NASDAQ:EDIT) vs. MeiraGTx (NASDAQ:MGTX)
americanbankingnews.com - November 3 at 1:23 PM
finance.yahoo.com logoEditas (EDIT) to Report Q3 Earnings: What's in the Cards?
finance.yahoo.com - November 2 at 1:06 PM
finance.yahoo.com logoShould You Scoop Up Shares of This Promising Biotech on the Dip?
finance.yahoo.com - October 28 at 7:47 AM
forbes.com logoIs It Time To Bet On Editas Stock’s Next Leg Lower?
forbes.com - October 27 at 3:45 PM
benzinga.com logoEditas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update
benzinga.com - October 25 at 4:04 PM
benzinga.com logoEditas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update
benzinga.com - October 25 at 4:04 PM
benzinga.com logoAnalyst Ratings For Editas Medicine
benzinga.com - October 19 at 7:34 PM
finance.yahoo.com logoInsiders in Editas Medicine, Inc. (NASDAQ:EDIT) are down 18% on their US$1.4m purchase despite recent gains
finance.yahoo.com - October 16 at 10:33 AM
finance.yahoo.com logo4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
finance.yahoo.com - October 14 at 12:23 PM
marketwatch.com logoEditas Medicine Shares Drop 11% in Heavy Trade
marketwatch.com - October 8 at 3:17 PM
finance.yahoo.com logoEditas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting
finance.yahoo.com - October 7 at 8:26 AM
msn.com logoPower players: These 12 young serial founders are building the next generation of biotech startups
msn.com - October 6 at 11:24 AM
finance.yahoo.com logoEditas (EDIT) Down on Initial Data From Eye Disease Study
finance.yahoo.com - September 30 at 12:58 PM
finance.yahoo.com logoEditas Stock Firestorm Rages On; CRISPR Gene-Editing Stock Flashes Sell Signal
finance.yahoo.com - September 30 at 12:58 PM
nasdaq.com logoRSI Alert: Editas Medicine Now Oversold
nasdaq.com - September 29 at 4:56 PM
bloomberg.com logoEditas Craters After Gene Therapy Disappoints, While Rival Rises
bloomberg.com - September 29 at 4:56 PM
bloomberg.com logoCrispr Is Still Promising, Even If Editas’s Experiment Falls Short
bloomberg.com - September 29 at 4:56 PM
finance.yahoo.com logoPreMarket Prep Stock Of The Day: Editas Medicine
finance.yahoo.com - September 29 at 4:56 PM
finance.yahoo.com logoEditas Medicine Stock Plunges As CRISPR Gene-Editing Drug Fails To Impress
finance.yahoo.com - September 29 at 4:56 PM
nasdaq.com logoFirst Week of January 2024 Options Trading For Editas Medicine
nasdaq.com - September 17 at 1:04 AM
benzinga.com logo'Fast Money Halftime Report' Picks For September 13
benzinga.com - September 13 at 10:22 PM
cnbc.com logoFinal Trades: Stryker, Editas Medicine, Oracle & more
cnbc.com - September 13 at 5:21 PM
finance.yahoo.com logoEditas Medicine Names Emma Reeve to Board of Directors
finance.yahoo.com - September 8 at 9:33 AM
stocknews.com logoWhy You Need to Avoid These 3 Downgraded Stocks
stocknews.com - September 7 at 11:59 AM
finance.yahoo.com logoWhy Is Editas (EDIT) Up 33.8% Since Last Earnings Report?
finance.yahoo.com - September 3 at 5:20 PM
finance.yahoo.com logoIs Editas Medicine (NASDAQ:EDIT) A Risky Investment?
finance.yahoo.com - September 1 at 5:16 PM
msn.com logoEditas Medicine Unveils Preclinical Data From New Gene Editing Technology
msn.com - August 23 at 8:50 AM
finance.yahoo.com logoEditas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting
finance.yahoo.com - August 20 at 5:18 PM
forbes.com logoWill The Rally In Editas Stock Continue After A 20% Rise In A Month?
forbes.com - August 11 at 7:41 PM
seekingalpha.com logoEditas Medicine, Inc. 2021 Q2 - Results - Earnings Call Presentation
seekingalpha.com - August 9 at 5:37 AM
benzinga.com logoEvercore ISI Group Upgrades Editas Medicine to Outperform, Raises Price Target to $60
benzinga.com - August 6 at 9:42 AM
markets.businessinsider.com logoEditas Medicine earnings: here's what Wall Street expects
markets.businessinsider.com - August 3 at 10:22 PM
benzinga.com logoThe global CRISPR market growth is anticipated to progress at a CAGR of 20.24% during the forecast period, 2021-2028
benzinga.com - August 3 at 7:20 AM
nasdaq.com logoEditas (EDIT) to Report Q2 Earnings: What's in the Cards?
nasdaq.com - August 2 at 11:06 AM
finance.yahoo.com logoEditas Medicine (EDIT) Stock Moves -0.1%: What You Should Know
finance.yahoo.com - July 30 at 7:47 PM
bizjournals.com logoThe Petri Dish: Newly SPAC'd Valo makes buy, Vertex launches CF trial
bizjournals.com - July 29 at 1:08 PM
benzinga.com logoAnalyzing Editas Medicine's Unusual Options Activity
benzinga.com - July 25 at 6:11 PM
finance.yahoo.com logoEditas Medicine Stock Shows Improved Relative Strength Rating
finance.yahoo.com - July 22 at 5:57 PM
marketwatch.com logoMolecular Scissors Technology Market Growth Report 2021- Size, Share, New Business Development Trends, Key Players and Outlook 2027
marketwatch.com - July 19 at 2:24 PM
ca.finance.yahoo.com logoLife Edit Therapeutics Announces Newly Established Scientific Advisory Board
ca.finance.yahoo.com - July 8 at 8:45 AM
Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.